Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...

Patients taking semaglutide, the active ingredient in Ozempic, were less likely to develop Alzheimer’s. Randomized clinical trials are needed to pin down the exact cause of this difference in risk.

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently approved only for type 2 diabetes, according to results from a small trial.

Medicare drug plans usually cover the pill form of semaglutide for type 2 diabetes. Learn more about coverage and costs.

CHICAGO — For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related events, with consistent findings in further analyses ...

A new study suggests semaglutide may lower dementia risk in type 2 diabetes patients, particularly among women and older adults. More research needed.

An analysis of 1.7 million patients shows semaglutide may significantly reduce Alzheimer and vascular dementia risk compared with other diabetes drugs.

A post-hoc analysis of STRIDE confirms the benefit of GLP-1 RA in patients with peripheral arterial disease and type 2 diabetes, but more research is needed in those without diabetes.

BrightGene beat semaglutide on a blood sugar endpoint, giving momentum as it barrels toward a readout from a head-to-head trial against tirzepatide.

BioNxt Launches Feasibility Study for Semaglutide Oral Thin Film as Alternative to Injection/Tablets Provided by ACCESS Newswire Jun 23, 2025, 12:05:00 AM ...

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar and leads to substantial weight loss in adults with type 1 diabetes ...

Diabetes treatment with semaglutide was associated with significantly reduced risk for stroke compared with empagliflozin, researchers reported.Risk for any CV events was not significantly ...